Hsia Yingfen, Maclennan Karyn
Centre for Paediatric Pharmacy Research, The School of Pharmacy, University of London, BMA House, Tavistock Square, London WC1H9JP, UK.
Eur J Epidemiol. 2009;24(4):211-6. doi: 10.1007/s10654-009-9321-3. Epub 2009 Mar 5.
The trend towards increased psychotropic drug prescribing in children and adolescents is well recognised in North America and continental Europe. However, it is unclear to what extent these studies are applicable to clinical practice in the United Kingdom (UK). This study was conducted to estimate the prevalence of psychotropic drug prescribing in children and adolescents aged <19 years in general practice in the UK from January 1992 to December 2001.
Data were obtained from the General Practice Research Database (GPRD). Annual age- and sex-specific prevalence of psychotropic drug prescribing was calculated.
A total of 143,079 prescriptions were issued to 34,398 study subjects. Stimulant prescriptions rose significantly from 0.03 per 1,000 (95% confidence interval 0.02-0.04) in 1992 to 2.9 per 1,000 (2.52-3.32) in 2001; a 96-fold increase. Methylphenidate accounted for the majority of stimulant prescriptions; 2.4% (349/14,370) of stimulant prescriptions were prescribed to children aged <6 years. Increased prescribing was also noted for antidepressants (1.6-fold), hypnotics/anxiolytics (1.3-fold), antipsychotics (1.3-fold) and anticonvulsants (1.3-fold), whilst the prevalence of clonidine and lithium prescribing remained fairly stable throughout the study period. The use of antidepressant, hypnotic/anxiolytic and anticonvulsant increased with increasing age. A high proportion of boys received stimulants, whereas antidepressants and hypnotics/anxiolytics were more likely prescribed to girls.
There is an increased trend of psychotropic drug use in children and adolescents in the UK practice. Since most psychotropic drugs are not licensed for use in children at this time, research is needed to investigate the efficacy and long-term safety in this population.
在北美和欧洲大陆,儿童和青少年中精神类药物处方增加的趋势已得到广泛认可。然而,这些研究在多大程度上适用于英国的临床实践尚不清楚。本研究旨在估算1992年1月至2001年12月期间英国全科医疗中19岁以下儿童和青少年精神类药物处方的患病率。
数据取自全科医疗研究数据库(GPRD)。计算了按年龄和性别划分的精神类药物处方年度患病率。
共向34398名研究对象开出了143079张处方。兴奋剂处方从1992年的每1000人0.03张(95%置信区间0.02 - 0.04)显著增至2001年的每1000人2.9张(2.52 - 3.32);增长了96倍。哌甲酯占兴奋剂处方的大部分;2.4%(349/14370)的兴奋剂处方开给了6岁以下儿童。抗抑郁药(1.6倍)、催眠药/抗焦虑药(1.3倍)、抗精神病药(1.3倍)和抗惊厥药(1.3倍)的处方也有所增加,而可乐定和锂盐处方的患病率在整个研究期间保持相当稳定。抗抑郁药、催眠药/抗焦虑药和抗惊厥药的使用随年龄增长而增加。高比例男孩使用兴奋剂,而女孩更可能使用抗抑郁药和催眠药/抗焦虑药。
在英国的实践中,儿童和青少年使用精神类药物有增加趋势。由于目前大多数精神类药物未获许可用于儿童,因此需要开展研究以调查该人群中的疗效和长期安全性。